학술논문
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
Document Type
Article
Author
Madhi, S.A.; Koen, A.L.; Izu, A.; Baillie, V.; Bhikha, S.; Jose, A.; Moultrie, A.; Mukendi, C.K.; Nana, A.J.; Nzimande, A.; Taoushanis, C.; Thombrayil, A.; Kwatra, G.; Fairlie, L.; Cutland, C.L.; Horne, E.; Masenya, M.; Patel, F.; van Eck, S.; Briner, C.; Hermanus, T.; Kgagudi, P.; Mkhize, N.; Moyo-Gwete, T.; Moore, P.L.; Padayachee, S.D.; Masilela, M.; Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; Aley, P.K.; Rhead, S.; Voysey, M.; Pollard, A.J.; Lambe, T.; Gilbert, S.C.; Villafana, T.L.; Vekemans, J.
Source
In: The Lancet HIV . (The Lancet HIV, September 2021, 8(9):e568-e580)
Subject
Language
English
ISSN
23523018